Clinitech Laboratory Ltd Stock Price Today (NSE: CTLLAB)
Fundamental Score
Clinitech Laboratory Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Clinitech Laboratory Ltd share price today is ₹35.00, down 6.23% on NSE/BSE as of 30 March 2026. Clinitech Laboratory Ltd (CTLLAB) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹9.90 (Cr). The 52-week high for CTLLAB share price is ₹57.00 and the 52-week low is ₹28.55. At a P/E ratio of 21.07x, CTLLAB is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 5.49% and a debt-to-equity ratio of 0.02.
Clinitech Laboratory Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Clinitech Laboratory Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Clinitech Laboratory Share Price: A Financial Stability Analysis
The healthcare service provider industry is experiencing a period of intense competition, driven by technological advancements and evolving patient expectations for faster and more convenient diagnostic services. Against this backdrop, this analysis examines the financial stability of Clinitech Laboratory Ltd. Clinitech Laboratory share price currently stands at ₹41.0, accompanied by a Price-to-Earnings (PE) ratio of 21.07 and a Return on Capital Employed (ROCE) of 8.15%. This report is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing an observational view of the company's financial health.
The PE ratio of 21.07 suggests that Clinitech Laboratory's share price reflects investor expectations of future earnings growth. However, a more in-depth examination is needed to ascertain if this valuation is justified by the company's performance and competitive positioning. Comparing Clinitech Laboratory Ltd with peers such as
Suraksha Diagnostic Ltd can shed light on relative valuations and management quality. It is important to assess aspects such as Suraksha Diagnostic Ltd's strategic initiatives and execution to understand how management decisions impact shareholder value compared to Clinitech.The ROCE of 8.15% is a crucial indicator of Clinitech Laboratory's profitability relative to the capital it employs. This return signifies how effectively the company generates profits from its investments in assets. An 8.15% ROCE implies that the company is producing moderate returns on its investments. It may be viewed as an indicator of moat strength, as a higher ROCE usually suggests a stronger competitive advantage. However, this ROCE also suggests that Clinitech's moat may be relatively weak and easily eroded if the organisation doesn't continue to innovate.
Considering the competitive landscape and the observed financial metrics, it's vital to monitor Clinitech Laboratory's future performance. Further analysis should include tracking revenue growth, cost management, and capital allocation strategies to determine the long-term sustainability of its current financial position. Examining these elements will help to evaluate whether the current Clinitech Laboratory share price reflects the company's underlying financial health and growth potential.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Clinitech Laboratory Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CTLLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (15.92%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.07 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (36.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.51%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (10.14x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (62.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (5.49%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Negative Free Cash Flow (₹-3.61 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.32%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Clinitech Laboratory Ltd Financial Statements
Comprehensive financial data for Clinitech Laboratory Ltd including income statement, balance sheet and cash flow
About CTLLAB (Clinitech Laboratory Ltd)
Clinitech Laboratory Ltd is a comprehensive healthcare service provider dedicated to delivering precise and reliable diagnostic solutions. With a steadfast commitment to patient we...ll-being, CTLLAB offers a wide spectrum of advanced laboratory testing, cutting-edge diagnostic imaging, and essential clinical services. Equipped with state-of-the-art technology and staffed by a team of highly skilled and experienced medical professionals, CTLLAB strives to provide timely and accurate results, empowering physicians to make informed decisions and optimize patient care. The organization's unwavering focus on quality assurance and adherence to stringent protocols ensures the highest standards of accuracy and reliability in every test and procedure performed. CTLLAB's extensive network of strategically located facilities provides convenient access to its comprehensive range of services. From routine blood tests to sophisticated molecular diagnostics, the laboratory offers a diverse menu of testing options to meet the evolving needs of its patients and healthcare partners. The diagnostic imaging centers are equipped with advanced modalities, including MRI, CT scans, ultrasound, and X-ray, enabling detailed visualization and assessment of internal structures. CTLLAB further enhances its service offering with ECG clinics, providing convenient access to essential cardiac monitoring. By integrating advanced technology with a patient-centric approach, CTLLAB is dedicated to providing accessible and high-quality healthcare services to the communities it serves. Committed to continuous improvement and innovation, Clinitech Laboratory Ltd actively invests in research and development to stay at the forefront of diagnostic advancements. The organization's robust quality management system ensures that all processes and procedures are rigorously monitored and optimized to maintain the highest standards of accuracy and reliability. CTLLAB is deeply rooted in a culture of integrity, transparency, and ethical practices, earning the trust and confidence of patients, physicians, and healthcare institutions alike. As a trusted healthcare partner, Clinitech Laboratory Ltd remains steadfast in its mission to provide exceptional diagnostic services and contribute to the well-being of the community.
Company Details
Key Leadership
CTLLAB Share Price: Frequently Asked Questions
What is the current share price of Clinitech Laboratory Ltd (CTLLAB)?
As of 30 Mar 2026, 12:02 pm IST, Clinitech Laboratory Ltd share price is ₹35.00. The CTLLAB stock has a market capitalisation of ₹9.90 (Cr) on NSE/BSE.
Is CTLLAB share price Overvalued or Undervalued?
CTLLAB share price is currently trading at a P/E ratio of 21.07x, compared to the industry average of 39.28x. Based on this relative valuation, the Clinitech Laboratory Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CTLLAB share price?
The 52-week high of CTLLAB share price is ₹57.00 and the 52-week low is ₹28.55. These values are updated daily from NSE/BSE price data.
What factors affect the Clinitech Laboratory Ltd share price?
Key factors influencing CTLLAB share price include quarterly earnings growth (Sales Growth: 24.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Clinitech Laboratory Ltd a good stock for long-term investment?
Clinitech Laboratory Ltd shows a 5-year Profit Growth of N/A% and an ROE of 5.49%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in CTLLAB shares.
How does Clinitech Laboratory Ltd compare with its industry peers?
Clinitech Laboratory Ltd competes with major peers in the Healthcare Service Provider. Investors should compare CTLLAB share price P/E of 21.07x and ROE of 5.49% against the industry averages to determine competitive standing.
What is the P/E ratio of CTLLAB and what does it mean?
CTLLAB share price has a P/E ratio of 21.07x compared to the industry average of 39.28x. Investors pay ₹21 for every ₹1 of annual earnings.
How is CTLLAB performing according to Bull Run's analysis?
CTLLAB has a Bull Run fundamental score of 45.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CTLLAB belong to?
CTLLAB operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Clinitech Laboratory Ltd share price.
What is Return on Equity (ROE) and why is it important for CTLLAB?
CTLLAB has an ROE of 5.49%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Clinitech Laboratory Ltd generates profits from shareholders capital.
How is CTLLAB debt-to-equity ratio and what does it indicate?
CTLLAB has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is CTLLAB dividend yield and is it a good dividend stock?
CTLLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Clinitech Laboratory Ltd shares.
How has CTLLAB share price grown over the past 5 years?
CTLLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CTLLAB and why does it matter?
Promoters hold 62.42% of CTLLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Clinitech Laboratory Ltd.
What is CTLLAB market capitalisation category?
CTLLAB has a market capitalisation of ₹10 crores, placing it in the Small-cap category.
How volatile is CTLLAB stock?
CTLLAB has a beta of N/A. A beta > 1 suggests the Clinitech Laboratory Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CTLLAB operating profit margin trend?
CTLLAB has a 5-year average Operating Profit Margin (OPM) of 15.92%, indicating the company's operational efficiency.
How is CTLLAB quarterly performance?
Recent quarterly performance shows Clinitech Laboratory Ltd YoY Sales Growth of 24.51% and YoY Profit Growth of 36.36%.
What is the institutional holding pattern in CTLLAB?
CTLLAB has FII holding of 0.32% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Clinitech Laboratory Ltd stock.